Recital 10, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

In forcesince 16 Apr 2014

Member States should efficiently assess all clinical trials applications within the given timelines. A rapid yet in-depth assessment is of particular importance for clinical trials concerning medical conditions which are severely debilitating and/or life threatening and for which therapeutic options are limited or non-existent, as in the case of rare and ultra-rare diseases.